Ketilept Retard 300mg 60 long-acting tablets — Made in Hungary — Free Delivery

Ketilept® Retard tablets are indicated for the treatment of:

As adjunctive therapy for major depressive episodes in patients with major depressive disorder (SID) who have a suboptimal response to antidepressant monotherapy. Before starting therapy, the doctor should carefully study the safety profile of Ketilept® retard.

Active ingredient: quetiapine;

1 long-acting film-coated tablet contains 57.56 mg, 172.680 mg, 230.24 mg, 345.36 mg 460.48 mg quetiapine fumarate (corresponding to 50 mg, 150 mg, 200 mg, 300 mg or 400 mg quetiapine );

Excipients: methacrylate copolymer (type A), lactose (spray dried SD 250), crystalline maltose (Advantose 100), talc, magnesium stearate, vegetable;

Shell composition: methacrylate copolymer (type A), triethyl citrate (Citrofol).

hypersensitivity to the components of the preparation;

concomitant use of inhibitors of cytochrome P450 3A4, such as inhibitors of HIV protease, azole-containing antifungals, erythromycin, clarithromycin and nefazodone.

There are different dosing regimens for each indication. It should be ensured that the patient is prescribed a dosage that is appropriate for their condition. The dose of the preparation and the duration of the course of treatment is determined by the doctor individually for each patient, depending on the indications and severity of the disease. For oral use. The preparation can be taken regardless of the meal. Tablets should be swallowed whole, without breaking, chewing or crushing them.

During pregnancy, the preparation can be prescribed only if the expected benefit outweighs the potential risk.

The preparation is not recommended for use in children due to the lack of data supporting its use in this age group.

Patients are not recommended to drive a car or other mechanisms until individual sensitivity to such effects is determined.

In general, the symptoms reported were due to an increase in the known pharmacological effects of the preparation, such as drowsiness and sedation, tachycardia and hypotension. There is no specific antidote for quetiapine. In severe cases, consideration should be given to the use of multidirectional measures and intensive care, including the restoration and maintenance of airway patency, provision of adequate oxygenation and ventilation of the lungs, monitoring and support of the cardiovascular system. Published reports describe cases of elimination of serious central nervous system (CNS) reactions, including coma and delirium, with intravenous administration of physostigmine (1-2 mg) under continuous ECG monitoring.